Atom Grants
Discover
  • Dashboard
  • Search
  • Deep Research
  • Favorites
  • Projects

    Targets to Therapies: Aggregation and Synuclein Biology Target Validation

    Forecasted

    Targets to Therapies: Aggregation and Synuclein Biology Target Validation supports researchers validating targets in aggregation and synuclein biology to guide therapeutic decisions for Parkinson’s disease.

    Browse similar grants
    Neuroscience Research Grants 2026Foundation Grants for Biomedical Research
    OverviewSimilar Grants
    OverviewSimilar Grants

    Funder: Michael J. Fox Foundation for Parkinson's Research

    Summary: Supports validation of aggregation and synuclein biology targets to advance therapeutic decisions for Parkinson’s disease.

    Key Information: Funded research outputs must be shared openly, free to access, and with persistent identifiers under MJFF’s Open Science Policy.


    Description

    The Michael J. Fox Foundation for Parkinson’s Research (MJFF) supports projects that build a robust evidence base for aggregation and synuclein biology targets with high potential relevance to Parkinson’s disease. The program funds work to clarify human relevance, define mechanisms in Parkinson’s-relevant contexts, establish target engagement, and develop enabling tools and assays.

    Supported research includes target modulation in cell and animal models to assess effects on Parkinson’s phenotypes, linking target biology to patient samples, and clarifying therapeutic mechanisms of action. Projects may also identify and test biomarkers for preclinical therapeutic validation and patient stratification, or characterize animal models to assess biological safety. The emphasis is on reproducible, translatable evidence that moves a defined target toward a therapeutic decision point.


    Atom

    See the full grant listing

    Sign in to view full eligibility details, sources, similar grants, and AI-powered analysis.